Detroit, MI 的 慢性淋巴性白血病 臨床試驗
7 項針對 慢性淋巴性白血病 的研究正在 Detroit(約 30 英里範圍內)及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本(英文)
正在為研究招募對象嗎?將此頁面置頂展示 — $99 / 30 天 →
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
招募中1/2 期
- Karmanos Cancer Institute, Detroit
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
招募中觀察性研究歡迎健康志工
- Henry Ford Hospital, Detroit
- Henry Ford Health Saint John Hospital, Detroit
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
招募中3 期
- Henry Ford Hospital, Detroit
- Henry Ford Health Saint John Hospital, Detroit
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
招募中3 期
- Karmanos Cancer Institute, Detroit
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
招募中2 期
- Karmanos Cancer Center, Detroit
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
招募中3 期
- Henry Ford Hospital /ID# 270973, Detroit
HPC Offered for PRESERVE Expansion
招募中觀察性研究
- Henry Ford Health, Detroit
其他城市的 慢性淋巴性白血病 試驗
- Boston, MA31 項研究
- Columbus, OH28 項研究
- Durham, NC27 項研究
- Washington, DC22 項研究
- Seattle, WA20 項研究
- Rochester, MN18 項研究
- New York City, NY18 項研究
- Houston, TX17 項研究
- Baldwin Park, CA16 項研究
- Milwaukee, WI15 項研究
- Chicago, IL14 項研究
- Cincinnati, OH14 項研究
Detroit 的其他研究
- 非小細胞肺癌44 項研究
- 乳癌33 項研究
- 癌症(所有類型)29 項研究
- 大腸直腸癌26 項研究
- 卵巢癌26 項研究
- 轉移性癌症24 項研究
- 前列腺癌22 項研究
- 子宮內膜癌21 項研究
- 肺癌20 項研究
- 多發性骨髓瘤19 項研究
- 胃癌16 項研究
- 頭頸部鱗狀細胞癌15 項研究
資料來源:ClinicalTrials.gov,擷取日期 2026年10月6日。各研究自行設定資格標準;由研究團隊決定參與者資格。